Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009;12(2):96-104.
doi: 10.1007/s11102-008-0097-3.

The effects of hyperprolactinemia on bone and fat

Affiliations
Review

The effects of hyperprolactinemia on bone and fat

Amal Shibli-Rahhal et al. Pituitary. 2009.

Abstract

Many patients with prolactin secreting pituitary tumors have decreased bone mineral. The bone loss is associated with an increase in bone resorption and is secondary to prolactin-induced hypogonadism. In both sexes trabecular bone in the spine and hip is more affected than cortical bone in the distal radius. Normalization of prolactin and restoration of gonadal function increases bone density but is not associated with normalization of bone mass. It is not known whether the bone loss in hyperprolactinemic subjects represents a failure to achieve peak bone mass or is due to accelerated bone loss. Despite low bone density hyperprolactinemic subjects do not demonstrate increased fractures. The association between prolactin, weight gain and obesity suggests that prolactin may also be a modulator of body composition and body weight. It is not known whether hyperprolactinemia associated weight gain is due to stimulation of lipogenesis or due to disruption of central nervous system dopaminergic tone. Hyperprolactinemia is also associated with insulin resistance and endothelial dysfunction which may improve after normalization of prolactin. The clinical significance of these findings and the precise role of prolactin in regulation of weight and metabolism remain to be elucidated.

PubMed Disclaimer

References

    1. Clin Endocrinol (Oxf). 1990 May;32(5):641-6 - PubMed
    1. J Clin Endocrinol Metab. 2003 Apr;88(4):1804-8 - PubMed
    1. Experientia. 1992 Mar 15;48(3):248-53 - PubMed
    1. J Endocrinol Invest. 1981 Apr-Jun;4(2):149-53 - PubMed
    1. Braz J Med Biol Res. 1993 Sep;26(9):933-41 - PubMed

LinkOut - more resources